Alpha-particle microdosimetry
- PMID: 22201713
- DOI: 10.2174/1874471011104030266
Alpha-particle microdosimetry
Abstract
With the increasing availability of alpha emitters, targeted α-particle therapy has emerged as a solution of choice to treat haematological cancers and micrometastatic and minimal residual diseases. Alpha-particles are highly cytotoxic because of their high linear energy transfer (LET) and have a short range of a few cell diameters in tissue, assuring good treatment specificity. These radiologic features make conventional dosimetry less relevant for that context. Stochastic variations in the energy deposited in cell nuclei are important because of the microscopic target size, low number of α- particle traversals, and variation in LET along the α-particle track. Microdosimetry provides a conceptual framework that aims at a systematic analysis of the stochastic distribution of energy deposits in irradiated matter. The different quantities of microdosimetry and the different methods of microdosimetric calculations were described in the early eighties. Since then, numerous models have been published through the years and applied to analyse experimental data or to model realistic therapeutic situations. Major results have been an accurate description of the high toxicity of α-particles, and the description of the predominant effect of activity distribution at the cellular scale on toxicity or efficacy of potential targeted α-particle therapies. This last factor represents a major limitation to the use of microdosimetry in vivo because determination of the source - target distribution is complicated. The future contributions of microdosimetry in targeted α-particle therapy research will certainly depend on the ability to develop high-resolution detectors and on the implementation of pharmaco-kinetic models at the tumour microenvironment scale.
Similar articles
-
Targeted alpha therapy: part I.Curr Radiopharm. 2011 Jul;4(3):176. doi: 10.2174/1874471011104030176. Curr Radiopharm. 2011. PMID: 22201706
-
Microdosimetry for targeted alpha therapy of cancer.Comput Math Methods Med. 2012;2012:153212. doi: 10.1155/2012/153212. Epub 2012 Sep 4. Comput Math Methods Med. 2012. PMID: 22988479 Free PMC article.
-
Modelling and dosimetry for alpha-particle therapy.Curr Radiopharm. 2011 Jul;4(3):261-5. doi: 10.2174/1874471011104030261. Curr Radiopharm. 2011. PMID: 22201712 Free PMC article. Review.
-
The promise of targeted {alpha}-particle therapy.J Nucl Med. 2005 Jan;46 Suppl 1:199S-204S. J Nucl Med. 2005. PMID: 15653670 Review.
-
MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.J Nucl Med. 2010 Feb;51(2):311-28. doi: 10.2967/jnumed.108.058651. Epub 2010 Jan 15. J Nucl Med. 2010. PMID: 20080889 Free PMC article.
Cited by
-
The potential and hurdles of targeted alpha therapy - clinical trials and beyond.Front Oncol. 2014 Jan 14;3:324. doi: 10.3389/fonc.2013.00324. eCollection 2014 Jan 14. Front Oncol. 2014. PMID: 24459634 Free PMC article. Review.
-
Targeting Prostate Cancer Stem Cells with Alpha-Particle Therapy.Front Oncol. 2017 Jan 9;6:273. doi: 10.3389/fonc.2016.00273. eCollection 2016. Front Oncol. 2017. PMID: 28119854 Free PMC article.
-
The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma.Target Oncol. 2015 Mar;10(1):15-26. doi: 10.1007/s11523-014-0324-y. Epub 2014 May 29. Target Oncol. 2015. PMID: 24870968 Review.
-
Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.AIMS Med Sci. 2015;2(3):228-245. doi: 10.3934/medsci.2015.3.228. Epub 2015 Aug 18. AIMS Med Sci. 2015. PMID: 26858987 Free PMC article.
-
Revisiting the Radiobiology of Targeted Alpha Therapy.Front Med (Lausanne). 2021 Jul 27;8:692436. doi: 10.3389/fmed.2021.692436. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34386508 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources